Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.76 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9430960 | 1.00 | USP2 (0.76) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL16496191 | 0.99 | LMNA (0.78) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL3667666 | 0.93 | LMNA (0.82) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL10971915 | 0.90 | LMNA (0.80) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL3667503 | 0.89 | LMNA (0.73) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL9431542 | 0.88 | LMNA (0.83) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| SCHEMBL16495871 | 0.87 | LMNA (0.70) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| Pirenzepine SCHEMBL41705 | 0.87 | LMNA (1.00) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| Pirenzepine SCHEMBL9254860 | 0.87 | LMNA (1.00) | USP2ALDH1A1LMNACYP1A2CHRM2 | |
| Pirenzepine SCHEMBL29793172 | 0.87 | LMNA (1.00) | USP2ALDH1A1LMNACYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300116-A1 | Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method | CELLAURA TECHNOLOGIES LTD (GB) | 2011-12-08 | — | — | US | disclosed |
| EP-2238248-A2 | A METHOD FOR GENERATING A RECOMBINANT CLONAL CELL LINE AND NOVEL REAGENTS FOR USE IN THE METHOD | Cellaura Technologies LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009040555-A2 | A METHOD FOR GENERATING A RECOMBINANT CLONAL CELL LINE AND NOVEL REAGENTS FOR USE IN THE METHOD | CELLAURA TECHNOLOGIES LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300116-A1 | Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method | HAVCR2, LDLR, ADGRF1 | USP2 3321/4885ALDH1A1 3246/4885LMNA 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.